Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Fusion provides contract services include...
- Antibody Humanization services
- Antibody Engineering Services
- Antibody sequencing Services
- Protein Expression & Purification Services
- Monoclonal Antibody services BLAST & Standard
- cGMP Services
Glythera is an early-stage Biotechnology company focused on the development of next-generation biologics, principally Antibody Drug Conjugates (ADCs) for cancer indications.
The Company’s ADC pipeline is based on an industry-leading, proprietary conjugation platform, ‘PermaLink’, which enables ADCs with higher therapeutic indices – a clear market need in fighting difficult-to-treat tumours. PermaLink is a cysteine-specific, non-maleimide approach that demonstrates significantly improved ADC conjugation stability and improved product homogeneity resulting in improved TI and patient safety profiles. Through PermaLink, Glythera is able to combine novel, highly potent toxins that induce apoptosis with novel antibodies that target cancer-specific antigens, especially those that are highly overexpressed in solid tumours.
The company is currently using its proprietary technology and access to a broad range of toxin payloads to develop a portfolio of class leading ADCs. Glythera is funded by IP Group and the North East Technology Fund and is based in Newcastle Upon Tyne, England
Horizon Discovery Group
IDACO Consulting Ltd
Advising and supporting academic institutions and start-up companies on out-sourcing strategies - looking for cost-effective solutions and accelerating the speed of progression and completion of projects.
Oversight and management of outsourced CMC and preclinical projects.
Undertaking due diligences on behalf of organisations in- and out-licencing development drug candidates.
Exploring innovative business models and opportunities for funding between academia and the out-sourcing network, looking to create collaborative win-win partnerships to progress projects.
Attending conferences and exhibitions on behalf of clients, evaluating new product opportunities and service providers.
Illingworth Research Ltd
IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development.
IA’s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.
Imanova has world-leading expertise in imaging sciences and their application to the understanding of disease and translational drug development. An innovative joint venture, Imanova’s shareholders are the UK's Medical Research Council and three world-class London universities: Imperial College London, King’s College London and University College London.
Imanova is a company with a depth of understanding in drug development and extensive experience using imaging to facilitate the development pipeline. Our academic expertise and extensive links with clinicians and scientists in our shareholder institutions provide unrivalled capabilities to facilitate drug development.
Innova Biosciences Ltd
J A Kemp
We are one of the largest UK and European Patent and Trade Mark Attorney firms, with offices in London, Oxford, Cambridge and Munich. The breadth and depth of our technical knowledge relevant to patents is outstanding, with over 70 science and technology graduates in the firm including over 30 PhDs. No area of science or technology is outside our scope.